Posted by Michael Wonder on 27 Jan 2023
Bristol Myers Squibb announces positive CHMP opinion for once daily Sotyktu (deucravacitinib) as a treatment for adults with moderate to severe plaque psoriasis
27 January 2023 - CHMP recommendation based on positive results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial.
Bristol Myers Squibb today announced that the CHMP of the EMA has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate to severe plaque psoriasis.
